TARA Latest Headlines

Protara Secures $75 Million to Advance TARA-002 and Broaden Clinical Pipeline

Market Chameleon (Fri, 5-Dec 7:29 AM)

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Protara Therapeutics (TARA)

at www.tipranks.com (Fri, 5-Dec 10:50 AM)

Why Ulta Beauty Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

at www.benzinga.com (Fri, 5-Dec 4:53 AM)

Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share

at seekingalpha.com (Fri, 5-Dec 1:01 AM)

TARA-002 Shows 72% Complete Response Rate in BCG-Naive NMIBC Patients—Phase 2 Trial Interim Data Revealed

Market Chameleon (Thu, 4-Dec 11:04 AM)

Protara announces proposed public offering

at seekingalpha.com (Thu, 4-Dec 4:31 PM)

TARA-002 Achieves 72% Complete Response Rate in Phase 2 NMIBC Trial, Highlighting Strong Potential in BCG-Naive Patients

Market Chameleon (Wed, 3-Dec 10:31 AM)

TARA-002 Achieves 72% Complete Response in BCG-Naïve NMIBC: Promising Data from ADVANCED-2 Trial

Market Chameleon (Wed, 3-Dec 8:34 AM)

Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating

at www.tipranks.com (Wed, 3-Dec 12:07 PM)

Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial

at www.tipranks.com (Wed, 3-Dec 11:57 AM)

Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positioning

at www.tipranks.com (Wed, 3-Dec 11:37 AM)

Protara Therapeutics reports positive results from bladder cancer study

at seekingalpha.com (Wed, 3-Dec 9:03 AM)

Protara Therapeutics Announces Promising Phase 2 Trial Results

at www.tipranks.com (Wed, 3-Dec 8:28 AM)

TARA-002 Delivers Robust Clinical Success in Pediatric Lymphatic Malformations: Interim STARBORN-1 Trial Results Stand Out

Market Chameleon (Wed, 19-Nov 8:23 AM)